Method and composition for treating and preventing mycobacterium infections

Abstract

Calanolides and analogues thereof that demonstrate potent mycobacterium activity are provided. Also provided is a method of using calanolides and analogues thereof for treating or preventing mycobacterium infections. The calanolides and analogues thereof provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.

What is claimed is:  
     
         1 . A method of preventing or treating a mycobacterium infection comprising administering to a mammal an effective amount of at least one compound of the formula I: 
                   
       wherein 
 R 1  is H, halogen, hydroxyl, amino, C 1-6  alkyl, aryl-C 1-6  alkyl, mono-or poly- fluorinated C 1-6  alkyl, hydroxy-C 1-6  alkyl, C 1-6  alkoxy, amino-C 1-8  alkyl, C 1-6  alkylamino, di(C 1-6  alkyl)amino, C 1-8  alkylamino-C 1-8  alkyl, di(C 1-6  alkyl) amino C 1-8  alkyl, cyclohexyl, aryl, or heterocycle, wherein aryl or heterocycle may each be unsubstituted or substituted with one or more of the following: C 1-6  alkyl, C 1-6  alkoxy, hydroxy-C 1-4  alkyl, hydroxyl, amino, C 1-6  alkylamino, di(C 1-6  alkyl) amino, amino-C 1-8  alkyl, C 1-8  alkylamino-C 1-8  alkyl, di(C 1-6  alkyl)amino-C 1-8  alkyl, nitro, azido or halogen;  
 R 2  is H, halogen, hydroxyl, C 1-6  alkyl, aryl-C 1-6  alkyl, mono- or poly- fluorinated C 1-6  alkyl, aryl or heterocycle;  
 R 3  and R 4  are independently selected from the group consisting of H, halogen, hydroxyl, amino, C 1-6  alkyl, aryl-C 1-6  alkyl, mono- or poly- fluorinated C 1-6  alkyl, hydroxy-C 1-6  alkyl, amino-C 1-8  alkyl, C 1-8  alkylamino-C 1-8  alkyl, di(C 1-6  alkyl)amino-C 1-8  alkyl, cyclohexyl, aryl or heterocycle; and R 3  and R 4  can be taken together to form a 5-7 membered saturated cycle ring or heterocyclic ring;  
 R 5  and R 6  are independently selected from the group consisting of H, C 1-6  alkyl, aryl-C 1-6  alkyl, mono- or poly-fluorinated C 1-6  alkyl, aryl or heterocycle; and R 5  and R 6  can be taken together to form a 5-7 membered saturated cycle ring or heterocycle ring;  
 R 7  is H, halogen, methyl, or ethyl;  
 R 8  and R 9  are independently selected from the group consisting of H, halogen, C 1-6  alkyl, aryl-C 1-6  alkyl, mono- or poly- fluorinated C 1-6  alkyl, hydroxy-C 1-6  alkyl, amino-C 1-8  alkyl, C 1-8  alkylamino-C 1-8  alkyl, di(C 1-6  alkyl)amino-C 1-8  alkyl, cyclohexyl, aryl or heterocycle; and R 8  and R 9  can be taken together to form a 5-7 membered saturated cycle ring or heterocyclic ring;  
 R 10  is halogen, O, OR 11 , NOR 11 , NHOR 11 , NOR 12 , NHOR 12 , NR 11 R 12 , NR 12 , or NR 12 R 13 ; wherein R 11  is H, acyl, P(O)(OH) 2 , S(O)(OH) 2 , CO(C 1-10  alkyl)CO 2 H, (C 1-8  alkyI)CO 2 H, CO(C 1-10  alkyl)NR 12 R 13 , (C 1-8  alkyl) NR 12 R 13 ; R 12  and R 13  are independently selected from the group consisting of H, C 1-6  alkyl, aryl, and aryl-C 1-6  alkyl; and R 12  and R 13  can be taken together to form a 5-7 membered saturated heterocyclic ring containing said nitrogen; or a pharmaceutically acceptable salt thereof.  
 
     
     
         2 . The method of    claim 1   , wherein the mycobacterium infection is selected from the group consisting of  Mycobacterium avium  complex (MAC),  Mycobacterium kansaii, Mycobacterium marinum, Mycobacterium phlei, Mycobacterium ulcerans, Mycobacterium xenopi, Mycobacterium gordonae, Mycobacterium terrae complex, Mycobacterium haemophilum, Mycobacterium fortuitum, Mycobacterium tuberculosis, Mycobacterium laprae, Mycobacterium scrofulaceum  and  Mycobacterium smegmatis.    
     
     
         3 . The method of    claim 1   , wherein the compound is selected from the group consisting of (+)-calanolide A, (−)-calanolide A, (±)-calanolide A, (−)-calanolide B, soulattrolide, and (−)-7,8-dihydrosoulattrolide.  
     
     
         4 . The method of    claim 1   , which further comprises co-administering an effective therapeutic amount of at least one compound selected from the group consisting of an anti-microbial agent, an antiviral compound, an immunostimulant, an immunomodulator, an antibiotic, or a chemokine inhibitor.  
     
     
         5 . The method of    claim 4   , wherein the anti-microbial agent is an anti-mycobacterial agent.  
     
     
         6 . The method of    claim 5   , wherein the mycobacterial agent is an anti-TB agent.  
     
     
         7 . The method of    claim 6   , wherein the anti-TB agent comprises isoniazid, rifampin, rifabutin, rifapentine, pyrazinamide or ethambutol.  
     
     
         8 . The method of    claim 4   , wherein the antiviral compound is a protease inhibitor.  
     
     
         9 . The method of    claim 8   , wherein the protease inhibitor is selected from the group consisting of indinavir, saquinavir, ritonavir, and nelfinavir.  
     
     
         13 . The method of    claim 4   , wherein the antiviral compound is a biflavanoid.  
     
     
         14 . The method of    claim 13   , wherein the biflavanoid is selected from the group consisting of robustaflavone, amentoflavone, and a derivative or salt thereof.  
     
     
         15 . The method of    claim 4   , wherein the antiviral compound is selected from the group consisting of AZT, ddC, ddI, D4T, 3TC, acyclovir, gancyclovir, fluorinated nucleosides and nonnucleoside analog compounds such as delavirdine and nevirapine, and efavirenz, α-interfon, recombinant CD4, amantadine, rimantadine, ribavirin, and vidarabine.  
     
     
         16 . The method of    claim 4   , wherein the immunostimulant is an interleukin or cytokine.  
     
     
         17 . The method of    claim 4   , wherein the antibiotic is an antibacterial agent, antifungal agent, or anti-pneumocysitis agent.